Fig. 1

HMGB1 accumulation and MMP-9/2 activity are increased in the plasma of CIPN patients and mice. A, B Plasma HMGB1 content (n = 20) and MMP-9 (n = 12) activity in cancer patients before L-OHP treatment (Control) and after the last L-OHP treatment (CIPN). The correlation between plasma HMGB1 and L-OHP dose (C) and plasma HMGB1 and VAS (D), respectively. VAS was performed after the last L-OHP treatment (n = 20). E The general scheme of experiments in vivo. F Mechanical thresholds of mice received L-OHP administration (3 mg/kg, i.p.) or vehicle for five consecutive days (n = 6). G and H HMGB1 content and MMP-9/2 activities in plasma of mice measured by western blotting and Gelatin zymography (n = 3). Plasma was collected from mice on the 14th day after the first administration of L-OHP (3 mg/kg, i.p.) or vehicle. Representative bands and a data summary (n = 3 for each group) are shown. A significant difference was revealed following unpaired Student’s t-test (A, B, G and H) or two-way ANOVA (F) or Linear regression analysis (C and D) (*p < 0.05, **p < 0.01 and ***p < 0.001 vs. Control; Bonferroni post hoc tests)